Literature DB >> 19026144

Mortality in rheumatoid arthritis: 2008 update.

T Sokka1, B Abelson, T Pincus.   

Abstract

Mortality rates in patients with rheumatoid arthritis (RA) are 1.5-1.6 fold higher than in the general population, with similar patterns over 60 years. The acute attributed causes of death appear overall similar to the general population, with cardiovascular disease the most common attributed cause of death, and with more infection, pulmonary and renal disease in RA than in the general population. All clinical measures indicating more severe clinical status appear prognostic of premature mortality, with rheumatoid factor and the shared epitope significant for progressive RA. Functional and global measures as well as comorbidities generally are the most significant predictors of premature death.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19026144

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  111 in total

1.  Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.

Authors:  Jeffrey R Curtis; Ani John; Onur Baser
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-09       Impact factor: 4.794

Review 2.  Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality.

Authors:  Elena Myasoedova; John M Davis; Cynthia S Crowson; Sherine E Gabriel
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

Review 3.  Nanotherapeutic approaches for the treatment of rheumatoid arthritis.

Authors:  Christine T N Pham
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-08-11

4.  Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis.

Authors:  Alexis Ogdie; Samantha Maliha; Daniel Shin; Thorvardur Jon Love; Joshua Baker; Yihui Jiang; Hyon Choi; Joel M Gelfand
Journal:  Rheumatology (Oxford)       Date:  2017-06-01       Impact factor: 7.580

5.  Skeletal muscle stem cell characteristics and myonuclei content in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Rasmus Jentoft Boutrup; Jean Farup; Kristian Vissing; Michael Kjaer; Ulla Ramer Mikkelsen
Journal:  Rheumatol Int       Date:  2018-04-12       Impact factor: 2.631

Review 6.  Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.

Authors:  Anthony S Russell; Wojtek P Olszynski; K S Davison; Cheryl Koehn; Boulos Haraoui
Journal:  Clin Rheumatol       Date:  2009-12-29       Impact factor: 2.980

Review 7.  Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance.

Authors:  M Kristen Demoruelle; Kevin Deane
Journal:  Curr Rheumatol Rep       Date:  2011-10       Impact factor: 4.592

8.  Identification of undiagnosed inflammatory arthritis in a community health fair screen.

Authors:  Kevin D Deane; Christopher C Striebich; Barbara L Goldstein; Lezlie A Derber; Mark C Parish; Marie L Feser; Elaine M Hamburger; Stacey Brake; Cindy Belz; James Goddard; Jill M Norris; Elizabeth W Karlson; V Michael Holers
Journal:  Arthritis Rheum       Date:  2009-12-15

9.  A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass.

Authors:  Monica Ibañez; Ana M Ortiz; Isabel Castrejón; J Alberto García-Vadillo; Inmaculada Carvajal; Santos Castañeda; Isidoro González-Alvaro
Journal:  Arthritis Res Ther       Date:  2010-03-23       Impact factor: 5.156

10.  Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy.

Authors:  Jennifer L Barton
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.